Lead, Financial Reporting

Lead, Clinical Operations

Lead, Trial Master File

Lead, Quality Control and Analytical Development

Lead, Toxicologist

Lead, Statistical Programming

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Amylyx is developing therapeutics for neurodegenerative disorders. A common feature of neurodegenerative diseases is neuronal death, which can be triggered when multiple stress factors are activated. Amylyx is identifying ways to preserve neurons by understanding the stress pathways that underlie Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. AMX0035, Amylyx’s lead program, has been shown in preclinical studies to protect neurons against death in a damage model by mitigating cellular stress and mitochondrial dysfunction. Following positive Phase 2 clinical results for ALS, AMX0035 is now being investigated in Phase 3 trials. Amylyx is also testing AMX0035 in patients with Alzheimer’s disease and Wolfram Syndrome. 

<p>Amylyx is developing therapeutics for neurodegenerative disorders. A common feature of neurodegenerative diseases is neuronal death, which can be triggered when multiple stress factors are activated. Amylyx is identifying ways to preserve neurons by understanding the stress pathways that underlie Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. AMX0035, Amylyx’s lead program, has been shown in preclinical studies to protect neurons against death in a damage model by mitigating cellular stress and mitochondrial dysfunction. Following positive Phase 2 clinical results for ALS, AMX0035 is now being investigated in Phase 3 trials. Amylyx is also testing AMX0035 in patients with Alzheimer’s disease and Wolfram Syndrome. </p>


Find a biotech startup job.